Alternative splicing and genetic variation of mhc-e: implications for rhesus cytomegalovirus-based vaccines

Commun Biol. 2022 Dec 19;5(1):1387. doi: 10.1038/s42003-022-04344-2.

Abstract

Rhesus cytomegalovirus (RhCMV)-based vaccination against Simian Immunodeficiency virus (SIV) elicits MHC-E-restricted CD8+ T cells that stringently control SIV infection in ~55% of vaccinated rhesus macaques (RM). However, it is unclear how accurately the RM model reflects HLA-E immunobiology in humans. Using long-read sequencing, we identified 16 Mamu-E isoforms and all Mamu-E splicing junctions were detected among HLA-E isoforms in humans. We also obtained the complete Mamu-E genomic sequences covering the full coding regions of 59 RM from a RhCMV/SIV vaccine study. The Mamu-E gene was duplicated in 32 (54%) of 59 RM. Among four groups of Mamu-E alleles: three ~5% divergent full-length allele groups (G1, G2, G2_LTR) and a fourth monomorphic group (G3) with a deletion encompassing the canonical Mamu-E exon 6, the presence of G2_LTR alleles was significantly (p = 0.02) associated with the lack of RhCMV/SIV vaccine protection. These genomic resources will facilitate additional MHC-E targeted translational research.

Publication types

  • Research Support, N.I.H., Extramural

MeSH terms

  • Alternative Splicing*
  • Animals
  • Cytomegalovirus
  • Cytomegalovirus Vaccines*
  • Genetic Variation
  • HLA-E Antigens
  • Histocompatibility Antigens Class I* / genetics
  • Humans
  • Macaca mulatta
  • Simian Immunodeficiency Virus

Substances

  • Cytomegalovirus Vaccines
  • Histocompatibility Antigens Class I